Current Clinical Trials
Last Update On: 4/15/2015


Open to Enrollment:

Breast Cancer


MSK 13-048 (Attempt Trial)

A Randomized Phase II Study of Adjuvant Trastuzuab Emtansine (T-DMI) vs. Paclitaxel in Cobination with Trastuzumab for Stage I HER2-Positive Breast Cancer


SWOG S1007


A Phase III, Randomized Clinical Trial of Standard Adjuvant Endocrine Therapy +/- Chemotherapy in Patients with 1-3 Positive Nodes, Hormone Receptor-Positive and HER2-Negative Breast Cancer with Recurrence Score (RS) of 25 or Less. RXPONDER: A Clinical Trial RX for Positive Node, Endocrine Responsive Breast Cancer


Colorectal Cancer


SWOG S1406


Randomized Phase II Study of Irinotecan and Cetuxiab with or without Vemurafenib in BRAF Mutant Metastatic Colorectal Cancer




RTOG 1010

A Phase III Trial Evaluating the Addition of Trastuzumab to Trimodality Treatment of Her2-Overexpressing Esophageal Adencarcinoma


Head and Neck Cancer


A Phase III Clinical Trial of Pembolizumab (MK-3475) in First Line Treatment of Recurrent/Metastatic Head and Neck Cancer

RTOG 0920
A Phase III Study of Postoperative Radiation Therapy (IMRT) +/- Cetuximab for Locally-Advanced Resected Head and Neck Cancer



ALCHEMIST Trials Adujvant Trials for Completely Resected Pateints EGFR or ALK Positive



Adjuvant Lung Cancer Enrichment Marker Identification and Sequencing Trial (ALCHEMIST)



Randomized Double-blind Placebo Controlled Study of Erlotinib or Placebo in Patients with Completely Resected Epidermal Growth Factor Receptor (EGFR) Mutant Non-Small Cell Lung Cancer (NSCLC)



A Phase III double-blind Trila for Surgically Resected Early Stage Non-Small Cell Lung Cancer:  Crizotinib versus Placebo for Patients with Tuors Harboring Anaplastic Lymphoma (ALK) fusion protein


RTOG 1306

A Randomized Phase II Study of Individual Combined Modality Therapy for Stage III Non-Small Cell Lung Cancer (NSCLC)




Astra Zeneca D4191C00001

A Phase III, Randomized, Double-Blind, Placebo-Controlled, Multi-Centre, International Study of MEDI4736 as Sequential Therapy in Patients with Locallty Advanced, Unresectable Non-Small Cell Lung Cancer (Stage III) who have not Progressedf following Definitive, Platinu-Bash, Concurrent Cheoradiation Therapy (PACIFIC)



A Phase III, Open-Label, Randomized Study to Investigate the Efficacy and Safety of MPDL3280A (Anti-PD-L1 Antibody) Compared with Best Supportive Care Following Adjuvant Cisplatin-Based Chemotherapy in PD-L1 Selected Patients with Copletely Resected Stage IB-IIIA Non-Small Cell Lung Cancer


First Line Metastataic


INCB 18424-266
A randomized, double-blind phase 2 study of Ruxolitinib or Placebo in combination with Pemetrexed/Cisplatin and Pemetrexed Maintenance for initial treatment of subjects with Nonsquamous Non-Small Cell Lung Cancer that is stage IIIB, stage IV, or Recurrent



A phase III, Open-Label, randomized study of MPDL3280A (Anti-PDL1 Antibody) compared with Gemcitabine + Cisplatin or Carboplatin for PD-L1-Selected, chemotherapy naive patients with stage IV squaous non-small cell lung cancer



A phase III, Multicenter, randomized, Open-Label study evaluating the efficacy and safety of MPDL3280A (anti-PD-L1 antibody) in combination with Carboplatin + NAB-Paclitaxel for chemotherapy-naive patients with stage IV non-squamous Non-small Cell Lung Cancer

Second Line Metastatic:

Galaxy-2 Trial; Protocol 9090-14 version 2.1 US (Synta)
A randomized, Phase 3 study of Ganetespib in combination with Docetaxel versus Docetaxel alone in patients with advanced Non-Small-Cell Lung Adencarcinoma

SWOG S1400

Phase II/III Biomarker-Driven master protocol for second line therapy of Squamous Cell Lung Cancer


ECOG E3612

A randomized phase II trial of Ipilimumab with or without Bevacizumab in patients with Unresectable Stage III or Stage IV Melanoma



Randomized Phase III Trial of Dabrafenib + Trametinib Followed by Ipilimumab + Nivolumab at Progression vs. Ipilimumab + Nivolumab Followed by Dabrafenib + Trametinib at Progression in Patients with Advanced BRAFV600 Mutant Melanoma


A Randomized Phase III Trial of Lenalidomide versus Observation Alone in patients with Asymptomatic High-Risk Smoldering Multiple Myeloma

Pancreatic Cancer


A Randomized, Multicenter, Double-Blind, Placebo-Controlled, Phase 2/3 Study of the Bruton's Tyrosine Kinase Inhibitor Ibrutinib in Combination with Nab-Paclitaxel and Gemcitabine versus Placebo in Combination with Nab-Paclitaxel and Gemcitabine, in the First Line Treatment of Patients with Metastatic Pancreatic Adencarcinoma


Prostate Cancer


CALGB 90203
A Randomized Phase III Study of Neo-Adjuvant Docetaxel And Androgen Deprivation prior To Radical Prostatectomy Versus Immediate Radical Prostatectomy In Patients With High-Risk, Clinically Localized Prostate Cancer.


Alliance A031201
Phase III trial of Enzalutimide (NSC #7660585) versus Enzalutamide, Abiraterone and Prednisone for castration resistant Metastatic Prostate Cancer

SWOG S1216
A Phase III Randomized Trial Comparing Androgen Deprivation Therapy + TAK-700 with Androgen Deprivation Therapy + Bicalutamide in Patients with newly Diagnosed Metastatic Hormone Sensitive Prostate Cancer

Sotio SP005

A randomized, double blind, multicenter, parallel-group, phase III study to evaluate efficacy and safety of DCVAC/Pca versus Placebo in men with Metastatic castration resistant Prostate Cancer eligible for 1st line cheotherapy

Renal Cell

SWOG S0931
EVEREST: EVErolimus for Renal Cancer Ensuing Surgical Therapy, a Phase III Study


Alliance A091401

Randomized Phase II Study of Nivolumab with or without Ipiliumab in Patients with Metastatic or Unresectable Sarcoma



Lung Screening


International Early Lung Cancer Action Program: Enrollment and Screening Protocol

Solid Tumors


Molecular Analysis for Therapy Choice (MATCH) Plus Sub Protocols for Treatment


Supportive Care


Evidera A-168679-00

Qualitative Research in Patients with NSCLC and Cachexia: Concept Elicitation and Cognitive Interviews


INCB-A-PV-401 Reveal

Prospective Observational Study of Patients with Polycythemia Vera in US Clinical Practices

Pfizer A4061070
Metastatic Renal Cell Cancer Registry (MaRCC registry)

Trumpet (Astellas) ONC-MA-1004

A Prospective Observational Cohort Study of Patients with Castration-Resistant Prostate Cancer (CRPC) in the United States

For more information on clinical trials please contact research@echoassociates.org.









Home | About Us | Services | Clinical Staff | Contact Us | Resources| Patient Info | Directions | Research & Clinical Trials

330 Washington Street, Suite 220 | Norwich, CT 06360
860-886-8362 | Fax 860-886-9262